MSD Reports 3% YoY Q3 2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio‑Pulmonary Portfolio
Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) today announced its third‑quarter 2025 financial results,...
Eli Lilly Reports 54% YoY Revenue Surge in Q3 2025, Raises Full‑Year Guidance to $63 B
Eli Lilly & Co. (NYSE: LLY) today announced that its third‑quarter 2025 financial results exceeded...
Jebel Pharma Reports Positive Phase III Results for JJH201501 Antidepressant
Jiangsu Jebel Pharma Co., Ltd. (SHA: 688566) today announced that its novel antidepressant JJH201501, developed...
Shanghai Bio‑Heart’s Iberis RDN System Gains UK MHRA Approval, Expands Global Commercial Reach
Shanghai Bio‑Heart Biological Technology Co., Ltd. (HKG: 2185) announced that its subsidiary, Shanghai AngioCare Medical...
Transcenta Partner Inhibrx Reports Positive ChonDRAgon Results for Ozekibart, Plans FDA BLA Filing in 2026
Transcenta Holding Limited (HKG: 6628) announced that its joint venture, Inhibrx Biosciences, Inc. (NASDAQ: INBX),...
HighTide Therapeutics Announces Positive Phase III Results for HTD1801 in Type 2 Diabetes
HighTide Therapeutics, Inc. (HKG: 2511) today announced that its two Phase III clinical trials, SYMPHONY‑1 (NCT06350890)...
Takeda Reports 3.9% YoY Revenue Decline in H1 2025, Citing Neuroscience Slump and FX Headwinds
Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) released its first‑half 2025 financial results today,...
BrightGene Submits HKEX Prospectus, Aiming for Main‑Board Listing
BrightGene Bio‑Medical Technology Co., Ltd. (SHA: 688166) filed its prospectus with the Stock Exchange of...
Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib
Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced its 2025 third‑quarter earnings today, reporting operating revenue...
JW Therapeutics & Regeneron Sign Expanded TCR‑T Collaboration, Unlocking $50 Million in Funding
JW Therapeutics Ltd. (HKG: 2126) announced today the signing of a supplementary strategic cooperation agreement...
Novo Nordisk Launches $9 Billion Unsolicited Bid for Metsera, Triggering Battle with Pfizer
Novo Nordisk A/S (NYSE: NVO) announced today an unsolicited offer of USD 9 billion for Metsera, Inc....
Thermo Fisher Secures $8.875B Clario Acquisition, Enhancing Digital‑Trial Endpoint Suite
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a definitive agreement to acquire Clario Holdings, Inc., a...
ModeX Therapeutics Locks $1 B+ Collaboration With Regeneron on Multispecific Antibody Technology
ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK) announced a milestone license and collaboration...
Everest Medicines Secures Exclusive Rights to VIS‑101 in Greater China, Potential 2026 Phase 3 Launch
Hong Kong‑listed Everest Medicines Limited (HKG: 1952) today announced a strategic agreement with Visara, Inc.,...
Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS
Bayer (ETR: BAYN) announced that the U.S. Food and Drug Administration had granted marketing approval...
Ascletis Launches ASC36, a Once‑Monthly Injectable Targeting Obesity
China‑based Ascletis Pharma Inc. (HKG: 1672) announced the selection of ASC36, a once‑monthly subcutaneous injectable...
Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200 M Deal
China‑based Pharmaron Beijing Co., Ltd. (HKG: 3759) announced on October 28, 2025 that it will acquire an...
Sihuan Pharmaceutical Partners with Abalone Bio to Accelerate Obesity Therapeutics Development
China‑based Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) and U.S. biotech firm Abalone Bio signed...
MediCare Negotiation Begins: 535 Generic Drugs Reviewed for 2025 Drug Catalogue
The 2025 National Medical Insurance (MediCare) Negotiation kicked off at 8:30 AM, marking the start of...
Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to €260 Million
Bayer AG (ETR: BAYN) announced that it has entered into a Share Purchase Agreement (SPA)...